Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Myriad Genetics (MYGN) Receivables - Other (2016 - 2021)

Myriad Genetics (MYGN) has disclosed Receivables - Other for 12 consecutive years, with $2.4 million as the latest value for Q1 2021.

  • Quarterly Receivables - Other fell 4.0% to $2.4 million in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Mar 2021, down 4.0% year-over-year, with the annual reading at $2.0 million for FY2020, N/A changed from the prior year.
  • Receivables - Other for Q1 2021 was $2.4 million at Myriad Genetics, up from $2.0 million in the prior quarter.
  • The five-year high for Receivables - Other was $6.9 million in Q3 2017, with the low at $2.0 million in Q3 2020.
  • Average Receivables - Other over 5 years is $4.1 million, with a median of $4.3 million recorded in 2018.
  • The sharpest move saw Receivables - Other soared 72.73% in 2017, then crashed 58.33% in 2020.
  • Over 5 years, Receivables - Other stood at $6.0 million in 2017, then dropped by 1.67% to $5.9 million in 2018, then crashed by 40.68% to $3.5 million in 2019, then tumbled by 42.86% to $2.0 million in 2020, then grew by 20.0% to $2.4 million in 2021.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $2.4 million, $2.0 million, and $2.0 million for Q1 2021, Q4 2020, and Q3 2020 respectively.